Epogen, Procrit, Retacrit

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical* ❑ *Home* ❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital* ❑ *Office* ❑ *Pharmacy*

Please indicate patient's therapy status:

❑ New start or re-start of therapy: Please complete the following forms in entirety and fax to 866-249-6155.
❑ Continuation of therapy: Please complete the following forms in entirety and fax to 866-249-6155.
❑ Therapy is complete: Please check box and fax first page to 866-249-6155.
❑ Therapy is on hold or patient has medication available: Please check box and fax first page to 866-249-6155.

Please retain the following form for submission when therapy resumes or when supply of medication is low.

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Exception Criteria Questions:

A. What drug is being prescribed?
- ❑ Epogen
- ❑ Procrit
- ❑ Retacrit, *Skip to Clinical Criteria Questions*
- ❑ Other _____, *Skip to Clinical Criteria Questions*

B. The preferred products for your patient's health plan are Aranesp, and Retacrit.
Can the patient's treatment be switched to a preferred product?
- ❑ Yes –Aranesp, *Please obtain Form for preferred product and submit for corresponding PA*
- ❑ Yes –Retacrit, *Skip to Clinical Criteria Questions*
- ❑ No

C. Has the patient experienced a documented intolerable adverse event with Retacrit? ***ACTION REQUIRED: If 'Yes', attach supporting chart note(s).*** ❑Yes ❑No

D. Was the documented intolerable adverse event an expected adverse event attributed to the active ingredient as described in the prescribing information? ***ACTION REQUIRED: If 'No', attach supporting chart note(s).***
❑ Yes ❑ No

E. Is the product being requested for one of the following indications?
- Treatment of anemia due to chronic kidney disease (CKD)
- Treatment of anemia due to myelosuppressive chemotherapy in a cancer patient

❑ Yes ❑ No *If No, skip to Clinical Criteria Questions*

F. Has the patient had a documented inadequate response or intolerable adverse event to treatment with Aranesp?
ACTION REQUIRED: If 'Yes', attach supporting chart note(s). ❑ Yes ❑ No

Clinical Criteria Questions:

1. Which drug is being prescribed? ❑ Epogen ❑ Procrit ❑ Retacrit ❑ Other _____

2. What is the patient's diagnosis?
- ❑ Anemia in chronic kidney disease (CKD)
- ❑ Anemia due to myelosuppressive chemotherapy
- ❑ Anemia in myelodysplastic syndrome (MDS)
- ❑ Presurgical use to reduce allogeneic blood transfusions
- ❑ Anemia in congestive heart failure (CHF)
- ❑ Anemia in rheumatoid arthritis
- ❑ Anemia due to hepatitis C treatment
- ❑ Anemia due to zidovudine treatment in a patient with HIV infection
- ❑ Anemia in patients whose religious beliefs forbid blood transfusions
- ❑ Anemia in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis
- ❑ Anemia due to cancer
- ❑ Other _____

3. What is the ICD-10 code? _____

4. What is the patient's hemoglobin (Hgb) level? *Exclude values due to recent transfusion*
Pretreatment (i.e., within 30 days of request): Hgb: _____ g/dL Date of lab: _____

Current (i.e., within 30 days of request): Hgb: _____ g/dL Date of lab: _____
❑ Unknown or lab not drawn

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

5. Will the requested medication be used concomitantly with other erythropoiesis stimulating agents (ESAs)?
   ❑ Yes ❑ No

6. Has the patient received erythropoiesis stimulating agent (ESA) therapy in the previous month (within 30 days of request)? ❑ Yes ❑ No *If No, skip to #9*

7. At any time since the patient started ESA therapy, has the patient's Hgb increased by 1 g/dL or more?
   ❑ Yes ❑ No

8. How many weeks of ESA therapy has the patient completed? _____ weeks:
   Document start date: _____

9. Has the patient been assessed for iron deficiency anemia? ❑ Yes ❑ No

10. What is the most recent serum transferrin saturation (TSAT) level? _____ % ❑ Unknown
    Document date Serum transferrin saturation (TSAT) level obtained: _____

11. Is the patient receiving iron therapy? ❑ Yes ❑ No

12. Is the patient undergoing palliative treatment? ❑ Yes ❑ No

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Anemia due to myelosuppressive chemotherapy

13. Does the patient have a non-myeloid malignancy? ❑ Yes ❑ No

Section B: Anemia due to Zidovudine Treatment in a Patient with HIV Infection

14. Is the patient currently receiving treatment with a zidovudine-containing medication? ❑ Yes ❑ No

Section C: Anemia due to Hepatitis C Treatment

15. Is the patient currently receiving treatment with ribavirin in combination with either interferon alfa or peginterferon alfa? ❑ Yes ❑ No

Section D: Presurgical Use to Reduce Allogeneic Blood Transfusions

16. Is the patient scheduled to have an elective, noncardiac, nonvascular surgery? ❑ Yes ❑ No

Section E: Anemia in myelodysplastic syndrome (MDS) or Anemia in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis

17. What is the patient's pretreatment serum erythropoietin level? _____ mU/mL ❑ Not available

Step Therapy Override: Complete if Applicable for the state of Maryland.	Please Circle	
Is the requested drug being used to treat stage four advanced metastatic cancer?	Yes	No
Is the requested drug's use consistent with the FDA-approved indication or the National Comprehensive Cancer Network Drugs & Biologics Compendium indication for the treatment of stage four advanced metastatic cancer and is supported by peer-reviewed medical literature?	Yes	No
Is the requested drug being used for an FDA-approved indication OR an indication supported in the compendia of current literature (examples: AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?	Yes	No
Does the prescribed quantity fall within the manufacturer's published dosing guidelines or within dosing guidelines found in the compendia of current literature (examples: package insert, AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?	Yes	No
Do patient chart notes document the requested drug was ordered with a paid claim at the pharmacy, the pharmacy filled the prescription and delivered to the patient or other documentation that the requested drug was prescribed for the patient in the last 180 days?	Yes	No
Has the prescriber provided proof documented in the patient chart notes that in their opinion the requested drug is effective for the patient's condition?	Yes	No

Step Therapy Override: Complete if Applicable for the state of Virginia.	Please Circle	
Is the requested drug being used for an FDA-approved indication or an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines)?	Yes	No
Does the prescribed dose and quantity fall within the FDA-approved labeling or within dosing guidelines found in the compendia of current literature?	Yes	No
Is the request for a brand drug that has an AB-rated generic equivalent or interchangeable biological product available?	Yes	No
Has the patient had a trial and failure of the AB-rated generic equivalent or interchangeable biological product due to an adverse event (examples: rash, nausea, vomiting, anaphylaxis) that is thought to be due to an inactive ingredient?	Yes	No
Is the preferred drug contraindicated?	Yes	No
Is the preferred drug expected to be ineffective based on the known clinical characteristics of the patient and the prescription drug regimen?	Yes	No
Has the patient tried the preferred drug while on their current or previous health benefit plan and it was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?	Yes	No
Is the patient currently receiving a positive therapeutic outcome with the requested drug for their medical condition?	Yes	No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720